MedImmune kept at neutral by Merrill

Merrill Lynch analyst Eric Ende maintained MedImmune Inc. at a neutral rating. The company reported fourth-quarter 2005 earnings per share of $0.08, higher than Merrill's estimate of $0.03 and consensus of $0.05. Merrill lowered its 2006 earnings-per-share estimate to $0.40 from $0.42, at the low end of guidance of $0.40 to 0.45, mainly due to a higher expected tax rate and higher expected operating expenses. Shares of the Gaithersburg, Md., biotechnology company were down 40 cents, or 1.22%, at $32.50 on volume of 3,459,899 shares versus the three-month running average of 2,048,990 shares. (Nasdaq: MEDI)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.